Late-Breaking Oral Session
Overview of Presentations with access to videos on demand (EHA subscription needed)
LINKS TO ABSTRACTS:
Presentation ID p205-1
(LB1901) OVERALL SURVIVAL RESULTS WITH DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: PHASE 3 MAIA STUDY
Presenter: Thierry Facon, Lille, France
The study authors conclude that after almost 5 years of follow-up, a significant and clinically meaningful overall survival improvement was demonstrated with the use of daratumumab plus lenalidomid and dexamethasone (D-Rd) versus lenalidomid and dexamethasone (Rd) in patients with NDMM who are transplant ineligible, representing a 32% reduction in the risk of death. The significant progression-free survival benefit of D-Rd versus Rd from the primary analysis (median follow-up, 28 months) was maintained, with a 47% reduction in risk of disease progression or death and a median progression-free survival for D-Rd NR. The favorable benefit-risk profile observed supports the use of D-Rd in transplant-ineligible patients with NDMM. These results, together with the overall survival benefit observed in ALCYONE, support the use of frontline DARA-based combination regimens to maximize progression-free survival for optimal long-term outcomes.
Presentation ID p205-2
(LB1902) FIXED-DURATION IBRUTINIB AND VENETOCLAX (I+V) VERSUS CHLORAMBUCIL PLUS OBINUTUZUMAB (CLB+O) FOR FIRST-LINE (1L) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE PHASE 3 GLOW STUDY
Presenter: Arnon Kater, The Netherlands
The study authors conclude that all-oral, once-daily, fixed duration ibrutinib plus venetoclax (FD I+V) demonstrated superior progression-free survival versus chlorambucil plus obinutuzumab (Clb+O) as first-line treatment for CLL, independent of the cumulative illness rating scale (CIRS) score and other covariates. I+V significantly improved depth and duration of remission and thus extended time to next treatment. Undetectable minimal residual disease with I+V was largely maintained 1 year after EOT. The safety profile for I+V was consistent with treatment in an elderly comorbid population. These first randomized data demonstrate the positive clinical profile of FD I+V in older patients.
Presentation ID p205-3
(LB1903) SAFETY AND EFFICACY OF CD37-TARGETING NARATUXIMAB EMTANSINE PLUS RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA AND OTHER NON-HODGKIN’S B-CELL LYMPHOMAS – A PHASE 2 STUDY
Presenter: Moshe Yair Levy, United States
The study authors conclude that the combination of naratuximab emantasine plus rituximab (nara + RTX) resulted in good OR and CR rates, durable responses, a manageable safety profile, and full CD37 target engagement. Consequently, nara + RTX could be considered an attractive option for the treatment of R/R DLBCL.
Presentation ID p205-4
(LB1904) A COMPARISON OF CLINICAL OUTCOMES FROM ZUMA-5 (AXICABTAGENE CILOLEUCEL) AND THE INTERNATIONAL SCHOLAR-5 EXTERNAL CONTROL COHORT IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
Presenter: John Gribben, London, United Kingdom
The study authors conclude that compared to currently available therapies in r/r FL patients, axicaptagene ciloleucel (axi-cel) demonstrated a substantial and statistically significant improvement in meaningful clinical endpoints including ORR, PFS, TTNT, and OS, highlighting the durable treatment effect of axi-cel. These findings suggest that axi-cel addresses an important unmet medical need for r/r FL patients.